A Multicenter, Open Label, 2 Period Cross-Over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Tobramycin (Primary)
- Indications Pseudomonal infections
- Focus Pharmacokinetics
- Sponsors Novartis
- 30 Nov 2015 Results published in the Journal of Antimicrobial Chemotherapy
- 31 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.